Vandetanib 300 mg

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Advanced Solid, Malignant TumorsAdvanced/Metastatic Medullary Thyroid Cancer (MTC)Symptomatic, Aggressive, Sporadic, Unresectable, Locally

Phase 1

Phase I Chinese PK

CompletedNCT00503711

Genzyme, a Sanofi CompanyAdvanced Solid, Malignant Tumors

Start: 2006-09-30End: 2007-11-30Updated: 2016-08-31

Unknown Phase

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer

CompletedNCT01945762

Genzyme, a Sanofi CompanyAdvanced/Metastatic Medullary Thyroid Cancer (MTC), Symptomatic, Aggressive, Sporadic, Unresectable, Locally

Start: 2014-02-17End: 2020-06-18Updated: 2024-12-18